• Earlier this month, Hims & Hers Health, Inc. resolved its legal dispute with Novo Nordisk and entered a renewed collaboration in which Novo Nordisk will supply branded GLP-1 weight-loss drugs like Ozempic and Wegovy through the Hims & Hers telehealth platform, while Hims & Hers stops promoting compounded versions except when clinically necessary.
• Ahead of its broader push into new health categories and geographies, Hims & Hers now pairs access to high-profile obesity treatments with an experienced new Chief Communications Officer, Kathryn Beiser, who has a track record shaping corporate brands in tightly regulated healthcare and financial sectors.
• We’ll now examine how this renewed Novo Nordisk partnership, especially access to branded GLP-1 obesity drugs, may reshape Hims & Hers’ investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers today, you have to believe its telehealth platform can keep turning strong subscriber growth into durable, profitable revenue across multiple health categories, not just weight loss. The renewed Novo Nordisk partnership directly affects the key short term catalyst, access to branded GLP‑1 obesity drugs, while also reducing a major legal and regulatory risk that had been hanging over its fastest growing segment.

Among recent developments, the appointment of Kathryn Beiser as Chief Communications Officer looks especially relevant here, because effective communication around GLP‑1 offerings, safety, and regulatory compliance could be critical as Hims & Hers expands into new “hard health” categories and international markets where scrutiny of obesity drugs and telehealth marketing is intense.

But behind the headline partnership, investors should also be aware of growing regulatory pressure on GLP‑1 pricing and marketing practices that could...

Hims & Hers Health's narrative projects $3.3 billion revenue and $261.3 million earnings by 2028. This requires 18.3% yearly revenue growth and about a $67.7 million earnings increase from $193.6 million today.

Uncover how Hims & Hers Health's forecasts yield a $44.36 fair value, a 79% upside to its current price.

Exploring Other Perspectives

Some of the most bearish analysts, who were assuming revenue of about US$3.1 billion and earnings near US$269 million by 2028, worry that tighter GLP‑1 regulation and pricing pressure could cap long term upside, so it is worth comparing their more cautious story with the renewed Novo deal before deciding which narrative you find more convincing.

Explore 57 other fair value estimates on Hims & Hers Health - why the stock might be worth 7% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.